CA2865203A1 — Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Assigned to AIC246 AG and Co KG · Expires 2013-09-06 · 13y expired
What this patent protects
The invention relates to pharmaceutical preparations, in particular for intravenous administration, which contain {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl} acetic acid in combination with at least one auxil…
USPTO Abstract
The invention relates to pharmaceutical preparations, in particular for intravenous administration, which contain {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl} acetic acid in combination with at least one auxiliary agent selected from the cyclodextrins, lysine, and arginine, to methods for the production thereof, and to the use thereof to treat and/or prevent diseases, in particular the use thereof as antiviral agents preferably against cytomegaloviruses.
Drugs covered by this patent
- Prevymis (LETERMOVIR) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.